Aim: Biosimilar medicines offer significant cost-savings potential over their reference products, which can be re-allocated to provide access to other cancer treatments on a budget-neutral basis. Methods: Simulation study using cost data for the USA under consideration of several prophylaxis patterns. Results: Potential savings from conversion from reference filgrastim to biosimilar filgrastim-sndz are significant. These savings expand budget-neutral access to novel immunotherapies (obinutuzumab; pembrolizumab) or supportive care (filgrastim-sndz). Conclusion: The combination of biosimilar savings and expanded access increases the value of cancer care as the same supportive care is provided at lower cost, additional cancer care is enabled at no additional cost, and more patients will have access to cancer care.
| Identifer | oai:union.ndltd.org:arizona.edu/oai:arizona.openrepository.com:10150/626506 |
| Date | 10 1900 |
| Creators | McBride, Ali, Balu, Sanjeev, Campbell, Kim, Bikkina, Mohan, MacDonald, Karen, Abraham, Ivo |
| Contributors | Univ Arizona, Ctr Canc, Dept Pharm, Univ Arizona, Dept Pharm Practice & Sci, Coll Pharm, Univ Arizona, Ctr Hlth Outcomes & PharmacoEcon Res, Univ Arizona, Dept Family & Community Med, Coll Med, Department of Pharmacy, Banner University Medical Center, Tucson, AZ 85719, USA, Sandoz Inc., Princeton, NJ 08540, USA, Sandoz Inc., Princeton, NJ 08540, USA, Sandoz Inc., Princeton, NJ 08540, USA, Matrix45, Tucson, AZ 85743, USA, Department of Pharmacy, University of Arizona Cancer Center, Tucson, AZ 85719, USA |
| Publisher | FUTURE MEDICINE LTD |
| Source Sets | University of Arizona |
| Language | English |
| Detected Language | English |
| Type | Article |
| Rights | © Abraham. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. |
| Relation | http://www.futuremedicine.com/doi/10.2217/fon-2017-0374 |
Page generated in 0.002 seconds